CareDx (NASDAQ:CDNA) Sets New 1-Year Low at $11.97

CareDx, Inc (NASDAQ:CDNAGet Rating) shares reached a new 52-week low on Tuesday . The stock traded as low as $11.97 and last traded at $11.97, with a volume of 3383 shares changing hands. The stock had previously closed at $12.46.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. StockNews.com raised shares of CareDx from a “sell” rating to a “hold” rating in a report on Friday, November 4th. The Goldman Sachs Group decreased their price objective on shares of CareDx from $45.00 to $40.00 and set a “buy” rating for the company in a report on Friday, November 4th. Raymond James decreased their price objective on shares of CareDx from $35.00 to $26.00 and set a “strong-buy” rating for the company in a report on Monday, November 7th. Finally, BTIG Research decreased their price objective on shares of CareDx from $37.00 to $28.00 and set a “buy” rating for the company in a report on Monday, November 7th. One analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, CareDx presently has a consensus rating of “Buy” and a consensus price target of $46.20.

CareDx Stock Up 2.3 %

The firm has a market capitalization of $680.46 million, a PE ratio of -9.01 and a beta of 1.03. The stock’s fifty day simple moving average is $16.62 and its 200 day simple moving average is $20.71.

Institutional Trading of CareDx

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Qube Research & Technologies Ltd bought a new position in shares of CareDx in the first quarter worth approximately $787,000. Teacher Retirement System of Texas boosted its position in shares of CareDx by 6.3% in the first quarter. Teacher Retirement System of Texas now owns 10,922 shares of the company’s stock worth $404,000 after purchasing an additional 647 shares during the period. Shell Asset Management Co. boosted its position in shares of CareDx by 152.9% in the second quarter. Shell Asset Management Co. now owns 5,953 shares of the company’s stock worth $128,000 after purchasing an additional 3,599 shares during the period. Searle & CO. bought a new position in shares of CareDx in the first quarter worth approximately $248,000. Finally, Walleye Capital LLC bought a new position in shares of CareDx in the second quarter worth approximately $781,000.

CareDx Company Profile

(Get Rating)

CareDx, Inc discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.

Read More

Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.